See more : The RMR Group Inc. (RMR) Income Statement Analysis – Financial Results
Complete financial analysis of Evelo Biosciences, Inc. (EVLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evelo Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Wealth Invest Linde&Partners Gl (WEILPGVF.CO) Income Statement Analysis – Financial Results
- Travel Technology Interactive (ALTTI.PA) Income Statement Analysis – Financial Results
- Olaplex Holdings, Inc. (OLPX) Income Statement Analysis – Financial Results
- William Penn Bancorporation (WMPN) Income Statement Analysis – Financial Results
- ATON Inc. (158430.KQ) Income Statement Analysis – Financial Results
Evelo Biosciences, Inc. (EVLO)
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.55M | 83.64M | 69.62M | 63.13M | 39.89M | 19.96M | 9.13M |
| General & Administrative | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Other Expenses | 0.00 | 486.00K | -1.37M | 1.08M | 1.16M | -301.00K | -20.00K |
| Operating Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Cost & Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Interest Income | 4.67K | 3.61K | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.67M | 3.61M | 2.11M | 1.05M | 1.56M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.06M | 2.22M | 2.03M | 1.76K | 1.94K | 834.00 | 495.00 |
| EBITDA | -106.35M | -115.40M | -91.89M | -86.36M | -58.10M | -26.70M | -12.53M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -108.47M | -115.40M | -91.89M | -86.36M | -58.10M | -27.53M | -13.03M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.13M | -6.35M | -1.37M | 885.00K | 1.16M | -516.00K | -307.00K |
| Income Before Tax | -113.60M | -121.75M | -93.26M | -85.47M | -56.95M | -28.05M | -13.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 930.00K | 428.00K | 409.00K | 190.00K | -3.09M | 215.00K | 287.00K |
| Net Income | -114.53M | -122.18M | -93.67M | -85.66M | -53.85M | -28.05M | -13.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.98 | -94.55 |
| EPS Diluted | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.55 | -94.06 |
| Weighted Avg Shares Out | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.00K | 141.00K |
| Weighted Avg Shares Out (Dil) | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.54K | 141.74K |
Evelo Biosciences: Clinical Data Coming Soon
Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
Lowest Insider Activity Since January - The Most Important Insider News (July 2020 Update)
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2020 Results - Earnings Call Transcript
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Evelo Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Evelo Biosciences (EVLO) Investor Presentation - Slideshow
Source: https://incomestatements.info
Category: Stock Reports